

Supplementary Table 1: Demographic and baseline data

Variables	Participants <i>n</i> =24
Gender	
Male	12 (50)
Female	12 (50)
Age	
Under 55	6 (25)
55-64	4 (16.7)
65 and over	14 (58.3)
Current Place of Care	
Private residence	22 (91.7)
Inpatient Oncology or Palliative ward	3 (12.5)
Married/living with partner	
Yes	12 (50.0)
No	12 (50.0)
Other, live in social support	
Yes	15 (62.5)
No	9 (37.5)
Community Support	
None	10 (41.7)
General Nursing	2 (8.3)
Palliative Care	6 (25)
Domestic	6 (25)
Other	2 (8.3)
Mobility aid use	
None	13 (54.2)
Walking Stick	6 (25)
4 Wheeled Walker	4 (16.7)
Other	1 (4.2)
Transport to clinic	
Drives self	5 (20.8)
Driven by someone	18 (75)
Public transport	3 (12.5)
Other	1 (4.2)
Metastatic disease	
Yes	21 (87.5)
No	3 (12.5)
Primary cancer	
Prostate	5 (20.8)
Breast	5 (20.8)
Lung	4 (16.7)
Gastro-intestinal	4 (16.7)
Melanoma	2 (8.3)
Urological	1 (4.2)
Gynaecological	1 (4.2)
Other	2 (8.3)
Current Treatment	
None	6 (25.0)
Chemotherapy	10 (41.7)

Hormone therapy	7 (29.2)
Bone strengthening	5 (20.8)
Immunotherapy	3 (12.5)
Number of medications, median (range)	11.5 (3-18)
Number of medications, mean (range)	11.23 (3-18)
Oral morphine equivalent dose in past 24 hours, median (range)	90mg (6-500mg)
Oral morphine equivalent dose in past 24 hours, mean (range)	122.29mg (6-500mg)
Use of other analgesia in past 24 hours (percentage)	75.0
HADS score, median (range)	13.45 (3-24)
Anxiety, median (range)	6.37 (0-12)
Depression, median (range)	7.08 (2-12)
Average pain score on day 1, median (range)	4.25 (2-9)

Data is presented as number (percentage) unless otherwise indicated.

